Abstracts Archive - Page 2413 of 2607 - ACR Meeting Abstracts

Abstract Number: 269 • 2013 ACR/ARHP Annual Meeting
Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment – Results Of The Phase III Program
Rayfel Schneider¹, Hermine Brunner¹, Nicolino Ruperto², Nico Wulffraat², Pierre Quartier³, Riva Brik², Liza McCann², Helen E. Foster², Michael Frosch², Valeria Gerloni², Liora Harel², Claudio Len², Kristin Houghton¹, Rik Joos², Ken Abrams⁴, Karine Lheritier⁵, Sophia Kessabi⁵, Alberto Martini² and Daniel J. Lovell¹, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ²Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Efficacy and safety of canakinumab (CAN), a selective, fully human, anti-interleukin-1β monoclonal antibody, in systemic juvenile idiopathic arthritis (SJIA) patients has been demonstrated in…
Abstract Number: 270 • 2013 ACR/ARHP Annual Meeting
Canakinumab In The Treatment Of Systemic Juvenile Idiopathic Arthritis: Results From a 12-Week Pooled Post-Hoc Analysis For Efficacy
Hermine Brunner¹, Pierre Quartier², Tamas Constantin³, Shai Padeh⁴, Inmaculada Calvo³, Muferet Erguven³, Laurence Goffin³, Michael Hofer⁵, Tilmann Kallinich³, Sheila Oliveira³, Yosef Uziel⁶, Stefania Viola⁷, Kiran Nistala³, Carine Wouters⁸, Karine Lheritier⁹, Josef Hruska⁹, Ken Abrams¹⁰, Alberto Martini³, Nicolino Ruperto³ and Daniel J. Lovell¹, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ²Necker-Enfants Malades Hospital, Paris, France, ³Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ⁴Sheba Medical Center, Tel-Hashomer, Israel, ⁵Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, ⁶Pediatric Rheumatology Unit , Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel, ⁷Istituto G. Gaslini, Istituto Giannina Gaslini, Genova, Italy, ⁸PRINTO, Genoa, Italy, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Interleukin-1β (IL-1β) plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA), a severe disabling subtype of JIA characterized by arthritis…
Abstract Number: 271 • 2013 ACR/ARHP Annual Meeting
Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE 3 Study
Hermine Brunner¹, Nicolino Ruperto², Tamás Constantin³, Nico Wulffraat^2,4, Gerd Horneff⁴, Jordi Anton², Reinhard Berner², Fabrizia Corona⁵, Rubén J. Cuttica⁶, Marine Desjonqueres², Michel Fischbach², Maria Alessio², Alice Chieng², Wolfgang Emminger², Elie Haddad⁷, Karine Lheritier⁸, Ken Abrams⁹, Josef Hruska⁸, Daniel J. Lovell⁷ and Alberto Martini², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ³Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, ⁴PRINTO, Genoa, Italy, ⁵PRINTO-Istituto Gaslini, Genova, Italy, ⁶Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁷Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Interleukin-1β (IL-1β) is a key cytokine in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective fully human anti-IL-1β monoclonal antibody,…
Abstract Number: 272 • 2013 ACR/ARHP Annual Meeting
Predictive Markers Of Joint Damages Of Children With Systemic-Onset Juvenile Idiopathic Arthritis In Long-Term Course Of Treatment With Tocilizumab
Tomo Nozawa, Taichi Kanetaka, Kenichi Nishimura, Masako Kikuchi, Tomomi Sato, Nodoka Sakurai, Ryoki Hara, Kazuko Yamazaki and Shumpei Yokota, Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (s-JIA) is a subtype of chronic childhood arthritis characterized by spiking fever, rash, and arthritis. Tocilizumab (TCZ), an anti-IL-6 receptor…
Abstract Number: 273 • 2013 ACR/ARHP Annual Meeting
Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti¹, Hermine Brunner², Eileen M. Baildam³, Ruben Burgos-Vargas³, Gerd Horneff³, Hans-Iko Huppertz³, Kirsten Minden⁴, Barry L. Myones², Karen Onel⁵, Jianmei Wang⁶, Kamal N. Bharucha⁷, Daniel J. Lovell², Alberto Martini⁸ and Nicolino Ruperto³, ¹IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ²PRCSG, Cincinnati, OH, ³PRINTO, Genoa, Italy, ⁴Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁵Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Genentech, South San Francisco, CA, ⁸Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: In the phase 3 TENDER trial of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA), decreases in neutrophil count were commonly observed.…
Abstract Number: 274 • 2013 ACR/ARHP Annual Meeting
Reported Macrophage Activation Syndrome In Patients With Systemic-Onset Juvenile Idiopathic Arthritis Treated With Tocilizumab
Shumpei Yokota^1,2, Yasuhiko Itoh^2,3, Tomohiro Morio^2,4, Naokata Sumitomo^2,5 and Seiji Minota^2,6, ¹Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ²The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan, ³pediatrics, Nippon Medical School, Tokyo, Japan, ⁴Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan, ⁵pediatrics, Nihon University School of Medicine, tokyo, Japan, ⁶Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (s-JIA) is a subtype of chronic childhood arthritis that is characterized by a spiking fever, rash, and arthritis. About 7%…
Abstract Number: 275 • 2013 ACR/ARHP Annual Meeting
Changes In Serum IL-18 Level In Systemic Juvenile Idiopathic Arthritis Patients Who Attained Drug-Free Remission By Tocilizumab
Tomohiro Kubota¹, Syuji Takei², Yuichi Yamasaki¹, Junko Yasumura³, Naomi Kuwada⁴, Yukiko Nonaka⁵, Tomoko Takezaki⁵, Tsuyoshi Yamatou⁵, Tomokazu Nagakura⁶, Yasuhito Nerome⁵, Hiroyuki Imanaka⁵ and Harumi Akaike⁵, ¹Dept of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ²School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Dept of Pediatrics, Graduate School of Biomedical Sciences, Faculty of Medicine, Hiroshima University, Hiroshima City, Japan, ⁴Dept of Pediatrics, Faculuty of Medicine, Kumamoto University, Kumamoto City, Japan, ⁵Department of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan, ⁶Department of Pediatrics, House of Meguminoseibo, Usuki, Japan
Background/Purpose: Tocilizumab (TCZ), anti-human interleukin-6 receptor monoclonal antibody, was the first biologic agent used in the treatment of systemic juvenile idiopathic arthritis (sJIA) in Japan.…
Abstract Number: 276 • 2013 ACR/ARHP Annual Meeting
Assessment Of Radiographic Progression In Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From The Tender Trial
Clara Malattia¹, Nicolino Ruperto¹, Elena Palmisani¹, Silvia Pederzoli¹, Angela Pistorio¹, Hermine Brunner², Rubén J. Cuttica³, Inmaculada Calvo¹, Stella Maris Garay¹, Despina Eleftheriou¹, Carine Wouters¹, Jianmei Wang⁴, Clare Devlin⁴, Daniel J. Lovell², Alberto Martini⁵, Fabrizio De Benedetti⁶ and Angelo Ravelli⁵, ¹PRINTO, Genoa, Italy, ²PRCSG, Cincinnati, OH, ³Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ⁶IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy
Background/Purpose: A phase 3 trial (TENDER) demonstrated the efficacy of the interleukin-6 receptor inhibitor tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA).1,2 The…
Abstract Number: 277 • 2013 ACR/ARHP Annual Meeting
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Standardized Consensus Treatment Plans for New Onset Polyarticular Juvenile Idiopathic Arthritis
Sarah Ringold¹, Pamela F. Weiss², Robert A. Colbert³, Esi Morgan DeWitt⁴, Tzielan C. Lee⁵, Karen Onel⁶, Sampath Prahalad⁷, Rayfel Schneider⁸, Susan Shenoi⁹, Richard K. Vehe¹⁰ and Yukiko Kimura¹¹, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ³NIAMS NIH, Bethesda, MD, ⁴Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁷Pediatrics, Emory Children's Center, Atlanta, GA, ⁸Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, ⁹Pediatric Rheumatology, Seattle Children's Hospital, University of Washington, Seattle, WA, ¹⁰Department of Pediatrics, University of Minnesota, Minneapolis, MN, ¹¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ
Background/Purpose: There is no standardized approach to the initial treatment of polyarticular juvenile idiopathic arthritis (pJIA) among North American pediatric rheumatologists. Understanding the comparative…
Abstract Number: 278 • 2013 ACR/ARHP Annual Meeting
Results Of a 24 Month Extension Study In Patients Who Participated In The Trial Of Early Aggressive Therapy In Polyarticular Juvenile Idiopathic Arthritis
Carol A. Wallace¹, John Bonsack², Steven J. Spalding³, Hermine Brunner⁴, Kathleen M. O'Neil⁵, Diana Milojevic⁶, Sarah Ringold⁷, Laura E. Schanberg⁸, Gloria C. Higgins⁹, Beth S. Gottlieb¹⁰, Joyce J. Hsu¹¹, Marilynn G. Punaro¹², Yukiko Kimura¹³ and Audrey F. Hendrickson¹⁴, ¹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, ³Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ⁶Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ⁸Pediatrics, Duke University Medical Center, Durham, NC, ⁹Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁰Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹¹Pediatric Rheumatology, Stanford University, Palo Alto, CA, ¹²Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹³Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁴Rheumatology, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: The Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT-JIA) was a double-blind, randomized, placebo-controlled trial in 85 patients with onset of…
Abstract Number: 279 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Adalimumab In Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 To <4 Years Or ≥4 Years Weighing <15 Kg
Daniel J. Kingsbury¹, Pierre Quartier², Vipin Arora³, Jasmina Kalabic⁴, Hartmut Kupper⁴ and Neelufar Mozaffarian³, ¹Randall Children's Hospital at Legacy Emanuel, Portland, OR, ²Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, ³AbbVie, North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe juvenile idiopathic arthritis (JIA) in patients (pts) ≥4 years (yrs) old in the US,…
Abstract Number: 240 • 2013 ACR/ARHP Annual Meeting
Longitudinal Femorotibial Cartilage Thickness Increase In Young Athletes At The End Of Adolescence
Felix Eckstein¹, Heide Boeth², Gerd Diederichs³, Wolfgang Wirth¹, Martin Hudelmaier⁴, Sebastian Cotofana⁵ and Georg Duda⁶, ¹Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria, ²Center for Sports Science and Sports Medicine, Julius Wolff Institute, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Department of Radiology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Paracelsus Medical University, Salzburg, Austria, ⁵Musculoskeletal Anatomy, Paracelsus Medical University, Salzburg, Austria, ⁶Julius Wolff Institute, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Anterior or posterior cruciate ligament (ACL/PCL) ruptures are thought to lead to early knee osteoarthritis (KOA) and thus considered scientifically valuable “models” of pre-radiographic…
Abstract Number: 241 • 2013 ACR/ARHP Annual Meeting
Exploratory Factor Analysis Of a Parsimonious Medial Cartilage Damage Index Reveals One Factor Associated With Radiographic Severity and Symptoms: Data From The Osteoarthritis Initiative
Grace H. Lo¹, Lori Lyn Price^2,3, Ming Zhang⁴, Jeffrey B. Driban⁵, Daniel Harper⁴ and Timothy E. McAlindon⁶, ¹VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Medical Care Line and Research Care Line; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, ²Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ³Biostatistics Research Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ⁴Rheumotology, Tufts Medical Center, Boston, MA, ⁵Rheumatology, Tufts Medical Center, Boston, MA, ⁶Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: The cartilage damage index (CDI) is a parsimonious method of measuring articular cartilage approximating regional cartilage volume based on 18 locations within the knee,…
Abstract Number: 242 • 2013 ACR/ARHP Annual Meeting
Elevated Systemic Blood Pressure Is Associated With Increased Prevalent Knee Osteoarthritis and Knee Pain: Data From The Osteoarthritis Initiative
Grace H. Lo¹, Timothy E. McAlindon², Jeffrey N. Katz³, Jeffrey B. Driban⁴, Lori Lyn Price^5,6, Charles Eaton⁷, Nancy Petersen⁸, Christie Ballantyne⁹ and Maria E. Suarez-Almazor¹⁰, ¹VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Medical Care Line and Research Care Line; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, ²Division of Rheumatology, Tufts Medical Center, Boston, MA, ³Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Tufts Medical Center, Boston, MA, ⁵Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ⁶Biostatistics Research Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ⁷Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, ⁸Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX, ⁹Department of Medicine, Baylor College of Medicine, Houston, TX, ¹⁰The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Epidemiologic studies have linked osteoarthritis (OA) to atheromatous vascular disease, both age-related diseases. Systemic hypertension (HTN) is an important risk factor for cardiovascular disease…
Abstract Number: 243 • 2013 ACR/ARHP Annual Meeting
The Association Between Metabolic Syndrome and Hand Osteoarthritis – Data From The Framingham Study
Ida K. Haugen¹, Vasan Ramachandran^2,3, Devyani Misra⁴, Tuhina Neogi⁴, Jingbo Niu⁴, Yuqing Zhang⁵ and David T. Felson⁵, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, MA, ³Cardiology, Boston University School of Medicine, Boston, MA, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Metabolic factors may have a negative effect on cartilage, and may be especially relevant in the pathogenesis of hand OA. Our aim was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].